AI Drug Developer Insilico Medicine Readies Brain-Penetrant Therapy For Parkinson’s Trials
Insilico Medicine reports it has finished IND-enabling work for ISM8969, an oral, blood-brain-barrier-penetrant NLRP3 inhibitor and aims to file an IND in Q4 2025 to start clinical evaluation in Parkinson’s disease. In preclinical MPTP models, the candidate reportedly produced dose-dependent motor gains (with significant effects at 20 mg/kg) with a supportive PK/PD package. Full datasets are not yet public.
In MPTP mouse models, the company reports dose-responsive improvements on open-field, rotarod, and grip-strength assays, with significant effects at 20 mg/kg, alongside a "balanced" druggability and safety profile.
The compound was nominated as a preclinical candidate in December 2024 and is part of Insilico’s broader effort to apply AI across the drug discovery and development pipeline. The company frames NLRP3 inhibition as a potential disease-modifying approach for Parkinson’s, positioning inflammation as a central driver of neurodegeneration.
"Current treatments often cause adverse effects that limit long-term use and do not address the underlying progression," said co-CEO Feng Ren.
The program targets the NLRP3 inflammasome with an oral small molecule designed to modulate neuroinflammation in a condition where approved therapies are largely symptomatic. The release cites a projection that ~25.2 million people may be living with Parkinson’s by 2050, framing the need for disease-modifying approaches.
Insilico attributes the program to its Pharma.AI stack, which spans target discovery to chemistry and development. According to the company, since 2021 it has nominated 22 development/preclinical candidates, received 10 IND clearances, and completed multiple human clinical trials for two advanced programs. It also reports internal efficiency benchmarks—an average 12-18 months from project start to development-candidate nomination with 60–200 molecules synthesized and tested per program.
The announcement follows a string of milestones for Insilico’s AI-derived pipeline. In June, Nature Medicine published Phase IIa results for rentosertib (ISM001-055), an AI-designed TNIK inhibitor for idiopathic pulmonary fibrosis. The same month, the company closed an oversubscribed Series E financing round at $123 million, backing ongoing clinical development and expansion of its AI and automation infrastructure. This includes the rollout of Supervisor, a bipedal lab robot integrated with Insilico’s PandaOmics target discovery system.
Topics: Clinical Trials
